NEW YORK (GenomeWeb) – Investment firm BTIG upgraded shares of molecular diagnostics firm T2 Biosystems, citing the market potential for a bacteria sepsis panel the company has under development.

Analyst Karen Koski upgraded T2 to a Buy rating from Neutral, putting a $16 target price on the company's shares. During late morning trading Friday, T2 stock was trading at $11.19.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.